A Humanised Anti-IL-17BR Monoclonal Antibody with Wide Therapeutic Potential in Allergic Asthma, Ulcerative Colitis, Pulmonary Fibrosis and Pancreatic Cancer

摘要

IL-17B receptors (IL-25 receptors) are expressed on innate lymphoid cells (ILC2s), which serve an important role in the initiation of type-2 immune responses and have recently been linked to complex roles in the transition from innate to adaptive immunity. ILC2s provide a critical source of type-2 cytokines, which in turn stimulate the effector response leading to inflammation. An anti-IL-17BR murine monoclonal antibody, D9.2, has been reported to attenuate disease phenotype in different in vivo mouse models involving the type-2 response namely; allergic asthma and ulcerative colitis (UC).